Exxel Pharma is focused on

• Commercialization of its FAAH inhibitor drugs and providing innovative medicines to current, unmet medical needs.
• Positioning URB937 as a novel treatment for chronic cough and a safe, non-addictive alternative to opioid drugs for pain management.
• Expanding the Company’s drug pipeline with follow-on molecules, and maximizing the value of the Company’s IP portfolio.
• Achieving the goal of providing optimal returns for our investors.